A B S T R A C T The emphysema associated with the inherited serum deficiency ofal-antitrypsin appears to result from an imbalance between neutrophil elastase and its major inhibitor within the alveolar structures. In the present study we assessed the feasibility of reversing this biochemical defect within the lung via parenteral replacement therapy with an al-antitrypsin concentrate of normal plasma. A 20-40% polyethylene glycol precipitate of pooled human donor plasma was used to obtain an enriched al-antitrypsin concentrate devoid of hepatitis B antigen and immunoglobulins. Using this material, five individuals with severe serum al-antitrypsin deficiency (PiZ phenotype) and advanced emphysema received 4 g ofal-antitrypsin intravenously at weekly intervals for four doses. During this period of weekly replacement therapy al-antitrypsin serum levels were maintained at .70 mg/dl, the level likely required for effective antielastase protection of the lung. In addition, assessment of lower respiratory tract antielastase activity by bronchoalveolar lavage demonstrated that parenteral replacement of a l-antitrypsin resulted in establishment of effective antielastase activity within the alveolar structures. There were no untoward side effects consequent to this approach to the replacement therapy of al-antitrypsin. These results demonstrate that the parenteral replacement of al-antitrypsin provides a means of obtaining elastase-antielastase balance within the lung of individuals with this serum protease inhibitor deficiency.
INTRODUCTION
al-Antitrypsin deficiency is a chronic, usually fatal autosomal codominant disorder in which a low concentration of serum al-antitrypsin is associated with pro-gressive, panacinar emphysema (1) (2) (3) (4) . The discovery of this association, together with the demonstration that enzymes with elastolytic activity induced emphysema when instilled into the lower respiratory tract of animals (5, 6) , have led to what is known as the "protease-antiprotease" theory of emphysema. This theory holds that in normal individuals, the alveolar structures of the lower respiratory tract are protected from proteases released by inflammatory cells by a normal antiprotease screen (7) . In the context of al-antitrypsin deficiency, therefore, the protease-antiprotease theory hypothesizes that the alveolar structures are unprotected, and thus are progressively distorted by proteases released by inflammatory cells present in the lower respiratory tract.
al-Antitrypsin is a glycoprotein of52,000 daltons produced in the hepatocyte and released into the circulation at a rate of 32 mg/kg per d (8, 9) . In normal individuals (so-called PiM, for "protease inhibitor" type M), this results in a serum al-antitrypsin level of 150-250 mg/dl. Direct evaluation of the antiprotease screen of PiM individuals has shown that al-antitrypsin represents >95% of the antielastase screen of the lower respiratory tract (10) .
In contrast, in the PiZ homozygote, the most common al-antitrypsin phenotype associated with emphysema, a substitution of a lysine for a glutamic acid in the alantitrypsin polypeptide chain appears to account for an abnormality in intracellular processing resulting in decreased secretion ofthe protein (11) . Thus, even though the PiZ al-antitrypsin molecule is just as efficient an antiprotease as the PiM molecule (2) , the reduced secretory rate of the PiZ protein results in a markedly decreased serum al-antitrypsin level, usually in the range of mg/dl (12) . Direct M  5  30  32  78  103   54  23  12  38  2  PiZ  37  M  4  20  42  51  115  62  39  10  35  3  PiZ  37  M  6  20  35  49  112  67  23  10  35  4   PiZ   66  F  8  0  43  111  103  38  51  8 PiZ homozygote vulnerable to unimpeded elastolytic attack (10) . Because al-antitrypsin is the major antiprotease of the lower respiratory tract, and because PiZ homozygote al-antitrypsin deficient individuals have insufficient al-antitrypsin in their serum (and hence in their alveolar structures) to protect the lower respiratory tract, the most direct and logical therapeutic approach to this inherited lung disease would be parenteral replacement of this missing antiprotease. The present study was designed to evaluate the feasibility of this approach. We have developed a relatively rapid and simple method for partially purifying al-antitrypsin from pooled human plasma. With the knowledge that the serum halflife of al-antitrypsin is 5.4 d (8), we devised an infusion schedule that would allow once weekly administration of al-antitrypsin to PiZ individuals, thus maintaining serum al-antitrypsin levels at >35% of normal, the level thought to be the serum threshold for antiprotease protection of the lower respiratory tract.
Using such a treatment schedule, we infused al-antitrypsin intravenously into five individuals each week for 4 wk. Importantly, direct evaluation of the antiproteases of the lower respiratory tract of these individuals demonstrated that following such infusions, significant amounts of al-antitrypsin with full antielastase activity do diffuse through the lower respiratory tract, thus likely affording protection to the alveolar structures from proteolytic attack. Replacement Therapy of aol-Antitrypsin Deficiency trypsin present in the starting material. Functional titration of this al-antitrypsin fraction demonstrated no significant reduction of specific inhibitory activity when assayed with purified neutrophil elastase (see below).
METHODS
Study design. After a routine medical examination, including liver and renal function tests, base-line levels of serum al-antitrypsin were measured. All participants were advised of the potential risks of the study and provided with a detailed explanation of the protocol design that had been approved by the National Institutes of Health Human Research Committee. In particular, subjects in this study were informed ofthe risk oftransfusion hepatitis before consent was obtained. Each individual then received the enriched al-antitrypsin preparation intravenously over a 6-8-h period at weekly intervals for 4 consecutive wk. Serum was obtained for antigenic and functional al-antitrypsin determinations (see below) immediately following the al-antitrypsin infusion and at daily intervals thereafter.
During the base-line period, and on days 10 and 24 (2 d after the second and fourth infusions, respectively), those patients with a forced vital capacity in one specond (FEV1) of >0.75 1 underwent fiberoptic bronchoscopy with lavage to evaluate the antiprotease screen oftheir lower respiratory tract (12) . Using previously described methods, the lavage material was collected, the cells pelleted, and the fluid evaluated for al-antitrypsin levels and antielastase function (see below). As previously described, all measurements were related to lavage fluid albumin levels to afford comparison to serum (13) .
At 2 wk and 6 mo following completion of the study, serum was obtained from each individual to evaluate the possibility of transmission of hepatitis B viral antigen during the course of the al-antitrypsin infusion. The serum samples were also used to evaluate possible production ofal-antitrypsin antibodies resulting from the infusions (see below).
Quantification of amount, type, and form of the al-antitrypsin in the lung and blood of the study population. Immunochemical determination of serum al-antitrypsin in the PiZ individuals during the course of the 4 wk study was performed with a standard radial immunodiffusion method (Calbiochem-Behring Corp., American Hoechst Corp., San Diego, Calif.) (14) . The results of these immunochemical determinations were then expressed as a percent of normal serum al-antitrypsin levels (normal levels were defined using a pool of normal PiM sera whose al-antitrypsin concentration was 200 mg/dl). The quantity of al-antitrypsin recovered by bronchoalveolar lavage was determined by "rocket" immunoelectrophoresis using the IgG fraction of monospecific goat antiserum to human al-antitrypsin (Atlantic Antibodies, Westbrook, Maine) (15) . Serum Evaluation of the antielastase protection to lung and blood afforded by al-antitrypsin infusions. Functional al-antitrypsin activity in serum and lower respiratory tract fluid was determined by measuring the capacity of a given sample to inhibit the action of 1.0 ,ug of purified neutrophil elastase (18, 19) on an insoluble [3Hlelastin substrate. Functional antielastase activity was expressed as the percent of total inhibition of 1.0 ,ug of neutrophil elastase achieved by each sample (20) .
,ug of neutrophil elastase achieved by each sample (19) .
Evaluation of serum for al-antitrypsin antibodies. Sera were obtained from each of the five PiZ patients 3-6 mo after completion ofthe al-antitrypsin infusion. These samples were assayed for the presence of precipitating antibody directed against the normal al-antitrypsin (M) protein by counterimmunoelectrophoresis in 1% agarose gels (0.2 M veronal acetate buffer, pH 8.2) (21).
RESULTS
Response of serum al-antitrypsin levels to al-antitrypsin infusions. Each of the five patients tolerated the four weekly infusions to the al-antitrypsin concentrate without significant adverse effects. The alteration of serum al-antitrypsin levels observed in two patients during the four weekly intravenous infusions of 4.0 g of al-antitrypsin are representative of the results obtained in all five subjects (Fig. 1) . In each patient, the peak of serum al-antitrypsin antigenic activity obtained immediately after the first infusion represented four-to fivefold increments over base-line levels. The serum al-antitrypsin levels then declined sharply for 2-3 d; this steep fall likely reflected redistribution of the administered al-antitrypsin throughout the extracellular space (a volume estimated at 1.8 times the plasma volume) as well as catabolism ofthe infused al-antitrypsin (8) .i A more linear portion of al-antitrypsin clearance from the serum was noted from day 3 to 7. The serum levels on days 3 and 7 following the initial infusion represented increments of 2.5-and 1.5-fold over pretherapeutic levels, respectively. These data suggest that the fractional catabolic rate ofthe al-antitrypsin administered intravenously was -12%/d, in close agreement with the studies of al-antitrypsin half-life carried out using radioiodinated al-antitrypsin (8) . This finding also suggests that the polyethylene glycol procedure used to prepare the plasma fraction in this study does not accelerate the clearance of al-antitrypsin from the circulation.
As expected from the study design, the "trough" al-antitrypsin level (day 7 after infusion) obtained just prior to the next al-antitrypsin infusion increased during each successive week of the study. For example, the trough serum al-antitrypsin levels obtained in patient 1 on successive weeks were 1.5, 1.65, 1.75, and 1.75 times the pretreatment level (Fig. 1A) . This presumably reflects the fact that with a fractional catabolic rate of 12%/d, nearly 30% of the infused al-antitrypsin remained within the extracellular compartment 7 d after administration.
As a group, the serum levels of al-antitrypsin in all five patients (in response to each of the infusions) was similar (Table II) . Each patient received four infusions at weekly intervals; for each of these infusions, the serum level achieved at day 2 after infusions was threeto fourfold that of the pretreatment level. Importantly, for each infusion, all patients maintained serum alantitrypsin levels in a range likely to provide antielastase protection for the alveolar structures.
Response of lower respiratory tract al-antitrypsin levels to the al-antitrypsin infusions. Because the therapeutic rationale for replacement therapy with alantitrypsin is to provide specific protection from the progressive, destructive lung disease associated with this serum antiprotease deficiency, it is important to examine the effect of the intravenous administration of al-antitrypsin on the extracellular milieu of the alveolar structures. To this end, four of the five participants in this study underwent fiberoptic bronchoscopy and saline lavage before the infusion and again after the second and fourth infusions. While there was no immunochemically detectable al-antitrypsin in their lower respiratory tract secretions before the administration of the al-antitrypsin concentrate, all patients had significant levels of al-antitrypsin per milligram albumin in their lavage fluid 2 d after infusion (Fig. 2 , Table II ). These lavage al-antitrypsin values represent -60% of the al-antitrypsin per milligram albumin recoverable from PiM subjects (10) . Analysis of the al-antitrypsin recovered from the alveolar structures during replacement therapy revealed that it displayed the same phenotypic pattern as the al-antitrypsin plasma fraction administered to the patients, i.e., while the patients were phenotype PiZ, the al-antitrypsin found on the epithelial surface of their lower respiratory tract 2 d after therapy was of phenotype PiM. The augmented levels of al-antitrypsin found in the lower respiratory tract after parenteral therapy likely resulted from diffusion of the intravenously administered al-antitrypsin from the plasma throughout the alveolar structures (data not shown).
Evaluation of the al-antitrypsin recovered by bronchoalveolar lavage during replacement therapy demonstrated that it was not complexed with protease when studied by crossed immunoelectrophoresis (data not shown). In addition, the functional al-antitrypsin increased in parallel with the quantity ofal-antitrypsin in the lower respiratory tract during replacement therapy (Figs. 2, 3C, and 3D) . Not tures, but it apparently does so in a form that theoretically can afford an effective antiprotease screen to the lower respiratory tract.
Effects of al-antitrypsin administration on serum and lower respiratory tract functional antielastase function. Because al-antitrypsin is the major elastase inhibitor of the lower respiratory tract, the critical clinical effect of al-antitrypsin deficiency appears to be the loss of elastase inhibitory activity within the alveolar structures. Thus, it is necessary to assess the effect of al-antitrypsin replacement therapy on the antielastase activity of the lower respiratory tract as a means of confirming the functional activity of the intravenously administered al-antitrypsin.
The serum antielastase activity of the study population following infusion ofal-antitrypsin concentrate increased in parallel with the al-antitrypsin antigenic activity ( Fig. 3A, B ; compare with Fig. 1 and Table II ). In a typical patient immediately after infusion, the serum antielastase activity rose from 24% to 82% of normal control serum. At midweek, the serum neutrophil elastase inhibitory activity was 60% of normal; immediately preceding the second infusion it was 35% of normal. On the average, an increment of 18 mg/dl of serum al-antitrypsin accounted for 10% increase in serum elastase inhibitory activity, similar to that expected in normal individuals. Thus, the infused al-antitrypsin retained nearly all of its biological activity in vivo.
Determination of the functional activity of the fluid recovered from the alveolar structures of the study population revealed that the lower respiratory tract antielastase activity increased markedly following parenteral al-antitrypsin replacement. For example, before therapy, lavage fluid from a typical patient inhibited only 15% of the neutrophil elastase activity observed with lavage fluid from a normal, PiM individual. In contrast, following the second and fourth infusions, lavage fluid antielastase activity rose to 60-70% of normal (Fig. 3C, D) . This increase in lower respiratory tract antielastase activity was commensurate with the 60% augmentation of immunochemical al-antitrypsin, demonstrating that the specific activity of the infused protein is preserved during diffusion into the alveolar structures (Figs. 2, 3C, and 3D ). These data confirmed that the infused al-antitrypsin reached the lower respiratory tract of the PiZ patients in a form that contributes to establishment of elastase-antielastase balance at the level of the alveolar structures.
Hazards of intravenous therapy with the al-antitrypsin concentrate. In this short-term study during which 320 The clinical significance of this short-term replacement study can be inferred from coinsideration of the serum and lower respiratory tract al-antitrypsin activity required to protect against the development of emphysema. While the issue has not been resolved conclusively, it appears that the risk of emphysema associated with the PiMZ phenotype (serum al-antitrypsin levels 55% of normal) does not greatly exceed that of the normal PiNI individual (22) (23) (24) (25) (26) (27) (28) (29) (30) . In contrast, the protection of the alveolar structures afforded by the serum levels associated with the PiZ phenotype (10-25% of normal) is clearly inadequate since it is estimated that at least 80% of these individuals will develop emphysemia (2) (3) (4) . Among serum al-antitrypsin level. Concommitant assessment ofal-antitrypsin function and levels recovered from the lower respiratory tract further suggests that a reasonable level of antielastase protection is afforded to the lung with this approach to replacement therapy. In addition, the appearance offunctional lung antielastase activity during the course of parenteral al-antitrypsin replacement further strengthens the concept that alantitrypsin is the primary inhibitor of neutrophil elastase within the lower respiratory tract of man (10) .
Direct replacement therapy of inherited deficiencies of serum proteins has demonstrated its value in such diverse inherited serum protein deficiencies as hemophilia (32), hypogammaglobulinemia (33) , and hereditary angioedema (34) . The present study suggests that al-antitrypsin prepared from pooled, normal human plasma provides a form of this elastase inhibitor with good specific activity and recovery rates that make replacement therapy on a maintenance schedule a feasible undertaking. In addition, the use of polyethylene glycol appears to confer a desirable safety margin with regard to the transmission of hepatitis. Also, there were no significant acute adverse reactions to the infusion or evidence of allotypic sensitization to the infused protein in this short study. By virtue of safety of administration and demonstrated bioactivity, this approach to the therapy of the emphysema associated with severe al-antitrypsin deficiency appears suitable for testing in long-term studies to determine if reestablishment of elastase-antielastase balance will mitigate the progression of this destructive lung disease (35) .
